Your browser doesn't support javascript.
loading
CRISPR-clear imaging of melanin-rich B16-derived solid tumors.
Schubert, Rajib; Bae, Taegeun; Simic, Branko; Smith, Sheena N; Park, Seong-Ho; Nagy-Davidescu, Gabriela; Gradinaru, Viviana; Plückthun, Andreas; Hur, Junho K.
Affiliation
  • Schubert R; Department of Biochemistry, University of Zürich, Zürich, Switzerland. rac0820@gmail.com.
  • Bae T; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. rac0820@gmail.com.
  • Simic B; Research and early development, Roche Sequencing Solutions, Pleasanton, CA, USA. rac0820@gmail.com.
  • Smith SN; Department of Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
  • Park SH; College of Pharmacy, The Catholic University of Korea, Gyeonggi-do, South Korea.
  • Nagy-Davidescu G; Department of Biochemistry, University of Zürich, Zürich, Switzerland.
  • Gradinaru V; Vector BioPharma AG, Basel, Switzerland.
  • Plückthun A; Department of Biochemistry, University of Zürich, Zürich, Switzerland.
  • Hur JK; Vector BioPharma AG, Basel, Switzerland.
Commun Biol ; 6(1): 370, 2023 04 04.
Article in En | MEDLINE | ID: mdl-37016073
ABSTRACT
Tissue clearing combined with deep imaging has emerged as a powerful technology to expand classical histological techniques. Current techniques have been optimized for imaging sparsely pigmented organs such as the mammalian brain. In contrast, melanin-rich pigmented tissue, of great interest in the investigation of melanomas, remains challenging. To address this challenge, we have developed a CRISPR-based gene editing approach that is easily incorporated into existing tissue-clearing workflows such the PACT clearing method. We term this method CRISPR-Clear. We demonstrate its applicability to highly melanin-rich B16-derived solid tumors, including one made transgenic for HER2, constituting one of very few syngeneic mouse tumors that can be used in immunocompetent models. We demonstrate the utility in detailed tumor characterization by staining for targeting antibodies and nanoparticles, as well as expressed fluorescent proteins. With CRISPR-Clear we have unprecedented access to optical interrogation in considerable portions of intact melanoma tissue for stained surface markers, expressed fluorescent proteins, of subcellular compartments, and of the vasculature.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanins / Melanoma Type of study: Diagnostic_studies Limits: Animals Language: En Journal: Commun Biol Year: 2023 Document type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanins / Melanoma Type of study: Diagnostic_studies Limits: Animals Language: En Journal: Commun Biol Year: 2023 Document type: Article Affiliation country: Switzerland